Safety in numbers - Monitoring risk in approved drugs

被引:45
作者
Okie, S
机构
关键词
D O I
10.1056/NEJMp058029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:1173 / 1176
页数:4
相关论文
共 4 条
[1]   National trends in cyclooxygenase-2 inhibitor use since market release - Nonselective diffusion of a selectively cost-effective innovation [J].
Dai, CL ;
Stafford, RS ;
Alexander, C .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (02) :171-177
[2]  
*GEN ACC OFF, 1990, GAOPEMD9015
[3]  
HARRIS G, 2005, NY TIMES 0220, pA28
[4]   Potential for conflict of interest in the evaluation of suspected adverse drug reactions - Use of cerivastatin and risk of rhabdomyolysis [J].
Psaty, BM ;
Furberg, CD ;
Ray, WA ;
Weiss, NS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (21) :2622-2631